Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 | P41143 | 1/20 | 0.44 |
| ▸ | SLC6A2 | P23975 | 13/20 | 0.43 |
| ▸ | SLC6A4 | P31645 | 13/20 | 0.43 |
| ▸ | SLC6A3 | Q01959 | 13/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 12/20 | 0.43 |
| ▸ | HTR7 | P34969 | 1/20 | 0.39 |
| ▸ | CES2 | O00748 | 1/20 | 0.37 |
| ▸ | CES1 | P23141 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3974848 | 0.86 | SLC6A2 (0.40) | OPRD1SLC6A2SLC6A4SLC6A3CYP2D6 | |
| SCHEMBL23467203 | 0.84 | SLC6A2 (0.47) | OPRD1SLC6A2SLC6A4SLC6A3CYP2D6 | |
| SCHEMBL414713 | 0.82 | SLC6A2 (0.62) | SLC6A2SLC6A4SLC6A3CYP2D6 | |
| SCHEMBL227735 | 0.79 | CES2 (0.41) | OPRD1HTR7CES2CES1 | |
| SCHEMBL25277087 | 0.78 | ALDH1A1 (0.44) | — | |
| Bromide SCHEMBL10966858 | 0.78 | OPRD1 (0.40) | OPRD1CES2CES1 | |
| SCHEMBL229151 | 0.77 | CES2 (0.42) | OPRD1CES2CES1 | |
| SCHEMBL230343 | 0.77 | CES2 (0.42) | OPRD1SLC6A3CES2CES1 | |
| SCHEMBL413666 | 0.75 | SLC6A2 (0.54) | OPRD1SLC6A2SLC6A4SLC6A3CYP2D6 | |
| SCHEMBL373783 | 0.74 | HDAC1 (0.42) | OPRD1CES2CES1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1928829-A1 | PIPERIDINE DERIVATIVES AS ANTAGONISTS OF THE CC CHEMOKINE RECEPTOR CCR1 AND THEIR USE AS ANTI-INFLAMMATORY AGENTS | Schering Aktiengesellschaft (DE) | 2008-06-11 | — | — | EP | disclosed |
| US-20060167044-A1 | Piperidine derivatives and their use as anti-inflammatory agents | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2006-07-27 | — | — | US | disclosed |
| WO-2006066948-A1 | PIPERIDINE DERIVATIVES AS ANTAGONISTS OF THE CC CHEMOKINE RECEPTOR CCR1 AND THEIR USE AS ANTI-INFLAMMATORY AGENTS | SCHERING AKTIENGESELLSCHAFT (DE) | 2006-06-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060167044-A1 | Piperidine derivatives and their use as anti-inflammatory agents | CCR1, CCR2, CCR3 | OPRD1 44/4885SLC6A2 4686/4885SLC6A4 4337/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.